Introducing
Precisebreast
PreciseBreast™ is designed specifically to speed the process of care planning for breast cancer patients.
PreciseBreast uses OncoIntelligenceTM to provide comprehensive insight into phenotype and grade, accurately predicting the risk of recurrence in hours.
Talk to Us
PreciseBreast® was previously validated on a Mount Sinai Health System cohort published in Breast Cancer Research, 2022. A further study, presented at SABCS 2024, extends these findings in a gene expression-tested cohort from Baptist Health Miami Cancer Institute in partnership with COTA, Inc. Trials are ongoing that aim to validate PreciseBreast for predicting treatment benefit.
For newly diagnosed women with invasive ductal carcinoma HR+, HER2-, Node -/+ (1-3), any menopausal status, no prior treatment.
View Full Poster
how precisebreast® works
PreciseBreast® deploys OncoIntelligenceTM to analyze the cellular morphology of tissue samples already collected – the same slides pathologists use for tumor grading. PreciseBreast® objectively classifies patients into two cohorts of low and high risk of tumor recurrence in hours, at 30% the cost of gene expression testing.
Oncologists can now confidently discuss results much faster than in the past to relieve patient anxiety and to allow for a more comprehensive shared decision making process.
With PreciseBreast®, patients and their physicians gain clarity, peace of mind, and an objective data point to base decisions on weeks sooner than they would with tumor grading alone.
PreciseBreast® delivers meaningful cost savings and better patient outcomes to healthcare systems.
PreciseBreast® requires no additional procedures or specialized staff for specimen collection, and it can be accessed from any geographical area in the US or the world.
Analytical validation of the PreciseBreast® technology
98%
Precision & Reproducibility
Tumor Segmentation
<2%
Variation of Assay Risk Score
Analytical validation of PreciseBreast demonstrates high precision across key factors (Fernandez, G., Zeineh, J. et al. Clinical Breast Cancer 2023 (NYSDOH))
Using PreciseBreastTM as well as visual pathologic analysis delivers benefits for patients, physicians, and payors.
.svg)
Data to drive precise analysis of recurrence risk
Faster results lessen anxiety for patients
.svg)
Lower overall testing and treatment costs
Availability to 100% of eligible patients
Aug 20, 2025
External validation of PreciseBreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands
See More
Aug 20, 2025
Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and compared its performance to other risk models.
See More
Jun 18, 2025
PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership
See More
Jun 18, 2025
Funding now totals over $43 million, strengthened leadership focused on a 2026 commercial launch of the OncoIntelligence™-driven, PreciseBreast™
See More
Dec 9, 2024
San Antonio Breast Symposium-24: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype
See More
Dec 9, 2024
San Antonio Breast Symposium-24: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospective study of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc.
See More
Contact us today to learn more about PreciseBreast.
